Fisher & Paykel Healthcare (ASX:FPH) has announced today a UK Court ruling that a patent asserted against it by ResMed (ASX:RMD) is invalid.
The case dates back to 2016, when Fisher & Paykel originally contested three of ResMed’s European patents and their use in the UK.
Only one ResMed patent associated with sleep apnea was ultimately bought to consideration by the court.
As a result of the ruling Fisher & Paykel is entitled to recover its legal costs from ResMed, for an amount yet to be determined by the court.
Shares in Fisher & Paykel Healthcare (ASX:FPH) last traded 0.91 per cent lower at $11.94.